Arkolith/Insider Trading/SYRE/Form 4

Burrows Scott L

Chief Financial OfficerSpyre Therapeutics, Inc. (SYRE) · full profile →Form 4 · filed Jun 4, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$533K
Net Open-Market Flow
-$533K
Transactions
5
4 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 1, 2026Option exercise(M)8K$14.50$109K105K
Jun 1, 2026Sell(S)2K$69.75$126K104K
Jun 1, 2026Sell(S)3K$70.77$184K101K
Jun 1, 2026Sell(S)3K$72.06$223K98K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 1, 2026Option exercise(M)8K—$0375K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001636282-26-000076) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML